Yahoo
NasdaqGS - Nasdaq Real Time Price USD

Upstream Bio, Inc. (UPB)

6.97 +0.12 (+1.75%)
At close: August 21 at 4:00:00 PM EDT
6.84 -0.13 (-1.87%)
After hours: August 21 at 7:30:07 PM EDT
Trade UPB on Coinbase
Chart Range Bar
Loading chart for UPB
  • Previous Close 6.85
  • Open 6.91
  • Bid 4.94 x 200
  • Ask 8.85 x 200
  • Day's Range 6.85 - 7.01
  • 52 Week Range 5.85 - 33.68
  • Volume 434,117
  • Avg. Volume 607,950
  • Market Cap (intraday) 381.754M
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) --
  • EPS (TTM) -2.88
  • Earnings Date (est.) Nov 4, 2026
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 33.50

Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease and in Phase I clinical trial for treating chronic obstructive pulmonary disease. The company was incorporated in 2021 and is headquartered in Waltham, Massachusetts.

upstreambio.com

75

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 8/21/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

UPB
74.33%
S&P 500 (^GSPC)
12.11%

1-Year Return

UPB
60.71%
S&P 500 (^GSPC)
20.47%

3-Year Return

UPB
67.58%
S&P 500 (^GSPC)
74.43%

5-Year Return

UPB
67.58%
S&P 500 (^GSPC)
72.78%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q1 FY26
Revenue 1.03M
Earnings -40.59M
Profit Margin -3,925.63%

Q3

FY25

Q4

FY25

Q1

FY26

-40M
-30M
-20M
-10M
0
-6000.0%
-5500.0%
-5000.0%
-4500.0%
-4000.0%

Analyst Insights

View More

Analyst Price Targets

9.00
33.50 Average
6.97 Current
75.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 8/14/2026
Analyst JP Morgan
Rating Action Maintains
Rating Neutral
Price Action Raises
Price Target 8 -> 9

Statistics

View More

Valuation Measures

Annual
As of 8/21/2026
  • Market Cap

    381.21M

  • Enterprise Value

    120.85M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    119.52

  • Price/Book (mrq)

    1.41

  • Enterprise Value/Revenue

    38.27

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -30.28%

  • Return on Equity (ttm)

    -46.05%

  • Revenue (ttm)

    3.16M

  • Net Income Avi to Common (ttm)

    -156.5M

  • Diluted EPS (ttm)

    -2.88

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    261.31M

  • Total Debt/Equity (mrq)

    0.35%

  • Levered Free Cash Flow (ttm)

    -86.62M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

6.97 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: